Immunology of hepatitis C;Inmunología de la hepatitis C

Revista de Investigacion Clinica

Volumn 51, Issue 5, 1999, Pages 315-322

  Alvarado Esquivel, Cosme ^a,c   Leroux Roels, Geert ^b  

^a UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

^b GHENT UNIVERSITY   (Belgium)

^c Inst de Investigacion Cientifica   (Mexico)

Author keywords

Hepatitis C; Immune response; Pathogenesis

Indexed keywords

CYTOKINE; HEPATITIS C ANTIBODY; HEPATITIS VACCINE;

BIOSYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; REVIEW; T LYMPHOCYTE;

CYTOKINES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; T-LYMPHOCYTES; VIRAL HEPATITIS VACCINES;

EID: 0008912799     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
2. Okamoto H, Kurai K, Okada SI, Yamamoto K, Lizuka H, Tanaka T et al. Full length sequence of a hepatitis C virus genome having poor homology to reported isolates: Comparative study of four distinct genotypes. Virology 1992; 188: 331-41.
3. Hijikata M, Mizushima H, Akagi T et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993; 67: 4665-75.
4. Stuyver L, Wyseur A, Van Arnhem W, Hernández F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996; 34: 22259-66.
5. Alvarado-Esquivel C, Wyseur A, Herrera-Ortiz FM, Ruiz-Maya L, Ruiz-Astorga R, Zárate-Aguilar A et al. Hepatitis B and C virus infections in Mexico: Genotypes and geographical distribution in blood donors and patients with liver disease. En: Schinazi RF, Sommadossi JP, Thomas HC (eds). Therapies for viral hepatitis. London: International Medical Press, 1998: 35-41.
6. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-9.
7. Stuyver L, Van Arnhem W, Wyseur A, DeLeys R, Maertens G. Analysis of the putative E1 envelope and NS4a epitope regions of HCV type 3. Biochem Biophys Res Commun 1993; 192: 635-41.
8. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. Hipervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Commun 1991; 175: 220-8.
9. Alter H. Natural history and clinical aspects of hepatitis C virus infection. En: Schinazi RF, Sommadossi JP, Thomas HC (eds). Therapies for viral hepatitis. London: International Medical Press, 1998: 43-50.
10. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
11. Serfaty L, Aumaitre H, Chazouilleres O, Bonnard AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1443-4.
12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
13. Goodman JW. La respuesta inmunitaria. En: Stiles D (ed). Inmunología básica y clínica. Mexico: El Manual Moderno, 1996: 51-63.
14. Hwang LH, Yang PM, Lai MY, Chiang BL, Kao JH, Wang JT et al. Identification of humoral antigenic determinants in the hepatitis C virus NS3 protein. J Infect Dis 1996; 174: 173-6.
15. Neville JA, Prescott LE, Bhattacherjee V, Adams N, Pike I, Rodgers B et al. Antigenic variation of core, NS3, and NS5 proteins among genotypes of hepatitis C virus. J Clin Microbiol 1997; 35: 3062-70.
16. Zhang ZX, Chen M, Hultgren C, Birkett A, Milich DR, Sallberg M. Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex. J Gen Virol 1997; 78: 2735-46.
17. Buratti E, Di Michele M, Song P, Monti Bragadin C, Scodeller EA, Baralle FE et al. Improved reactivity of hepatitis C virus core protein epitopes in a conformational antigen presenting system. Clin Diagn Lab Immunol 1997; 4: 117-21.
18. Tran A, Yang G, Dreyfus G, Rouquie P, Durant J, Rampal P et al. Significance of serum immunoglobulin M to hepatitis C virus core in patients with chronic hepatitis C. Am J Gastroenterol 1997; 92: 1835-8.
19. Ounanian-Paraz A, Morel-Baccard C, Barlet V, Gueddah N, Schweizer B, Bensa JC et al. HCV-Infection in blood donors: Association between anti-HCV core IgM antibodies and serum HCV RNA. Vox Sang 1996; 70: 139-43.
20. Quiroga JA, Pardo M, Navas S, Martin J, Carreno V. Patterns of immune responses to the host-encoded GOR and hepatitis C virus core-derived epitopes with relation to hepatitis C viremia, genotypes, and liver disease severity. J Infect Dis 1996; 173: 300-5.
21. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 1998; 27: 223-7.
22. Lee JW, Kim KM, Jung SH, Lee KJ, Choi EC, Sung YC et al. Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. J Virol 1999; 73: 11-8.
23. Enomoto N, Sato C, Kurosaki M, Marumo F. Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene. J Hepatol 1994; 20: 252-61.
24. Goeser T, Muller HM, Solbach C, Gmelin K, Kurzen F, Kommerell B et al. Prevalence and serological manifestation of hepatitis C virus infection in patients with hepatitis non-A, non-B: A follow-up study. Presse Medicale 1994; 23: 793-6.
25. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Ohkawa K, Fusamoto H et al. Hepatitis C virus replication and antibody responses toward specific hepatitis C virus proteins. Hepatology 1994; 19: 1360-5.
26. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286-95.
27. Leroux-Roels G, Alvarado-Esquivel C, DeLeys R, Stuyver L, Elewaut A, Philippe J et al. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alpha. Hepatology 1996; 23: 8-16.
28. Alvarado-Esquivel C, Philippé J, Elewaut A, Paradijs J, Elewaut AE, Deleys R et al. Evolution of HCV-specific T cell responses and in vivo and in vitro TNF-alpha and interferon-gamma production in chronic HCV patients treated with high doses of Interferon-alpha. Gastroenterology 1995; 108 (suppl): A1026.
29. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-14.
30. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Juang MC, Wierenga EA et al. Immunodominant CD4+ T cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011-9.
31. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158: 1473-81.
32. Nelson DR, Lau JYN. Pathogenesis of chronic hepatitis C virus infection. En: Schinazi RF, Sommadossi JP, Thomas HC. Therapies for viral hepatitis. London: International Medical Press, 1998; 65-76.
33. Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 1997; 4 (suppl 2): 31-41.
34. Cerny A, Fowler P, Brothers MA, Houghton M, Schlicht HJ, Chisari FV. Induction in vitro of a primary human antiviral cytotoxic T cell response. Eur J Immunol 1995; 25: 627-30.
35. Kita H, Moriyama T, Kaneko T, Harase I, Nomura M, Miura H et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993; 18: 1039-44.
36. Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, Sette A. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 1999; 162: 1156-64.
37. Tsai SL, Huang SN. T cell mechanisms in the immunopathogenesis of viral hepatitis B and C. J Gastroenterol Hepatol 1997; 12: S227-35.
38. Oppenheim JJ, Ruscetti FW, Faltynek C. Citocinas. En: Stiles D, Ed. Inmunología básica y clínica. México: El Manual Moderno, 1996: 133-55.
39. Torre D, Zeroli C, Giola M, Ferrario G, Fiori GP, Bonetta G et al. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis 1994; 18: 194-8.
40. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC Detection of type 2-like T helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-58.
41. Reiser M, Marousis CG, Nelson DR, Lauer G, Gonzalez-Peralta RP, Davis GL et al. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol 1997; 26: 471-8.
42. Bertoletti A, D'Elios MM, Boni C, De-Carli M, Zignego AL, Durazzo M et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193-9.
43. Iwata K, Wakita T, Okumura A, Yoshioka K, Takayanagi M, Wands JR et al. Interferon gamma production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection. Hepatology 1995; 22: 1057-64.
44. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487-94.
45. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72: 3691-7.
46. Feinstone SM. The virology of hepatitis C. J Gastroenterol Hepatol 1991; 1: 26-8.
47. Dienes HR Hutteroth T, Hess G, Meuer SC. Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B. Hepatology 1987; 7: 1317-25.
48. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 1992; 15: 572-7.
49. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC et al. Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterotogy 1993; 104: 595-603.
50. Chu HW, Dash S, Gerber MA. Genomic and replicative hepatitis C virus RNA sequences and histologic activity in chronic hepatitis C. Hum Pathol 1994; 25: 160-3.
51. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22: 418-25.
52. Koziel MJ, Walker BD. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol 1997; 19: 69-83.
53. Hashimoti E, Kojimahara N, Noguchi S, Taniai M, Ishiguro N, Hayashi N. Immunohistochemical characterization of hepatic lymphocytes in acute hepatitis A, B, and C. J Clin Gastroenterol 1996; 23: 199-202.
54. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M et al. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 1995; 95: 2067-75.
55. Marrogi AJ, Cheles MK, Gerber MA. Chronic hepatitis C. Analysis of host immune response by immunohistochemistry. Arch Pathol Lab Med 1995; 119: 232-7.
56. Garcia-Monzon C, Garcia-Buey L, Garcia-Sanchez A, de-Castro-Marinas M, Muñoz-Gomez R, Pajares JM et al. Tissue expression of antigenic recognition and intercellular adhesion molecules in chronic viral hepatitis. Rev Esp Enferm Dig 1993; 84: 301-9.
57. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997; 159: 1012-8.
58. Manns MP, Obermayer Straub P. Viral induction of autoimmunity: Mechanisms and examples in hepatology. J Viral Hepat 1997; 4 (suppl 2): 42-7.
59. Longombardo G, Ferri C, Marchi S, Costa F, Lombardini F, Vacri L et al. Immune response to an epitope of the NS4 protein of hepatitis C virus in HCV-related disorders. Clin Immunol Immunopalhol 1998; 87: 124-9.
60. Verbaan H, Carlson J, Eriksson S, Larsson A, Liedholm R, Manthorpe R et al. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients. J Intern Med 1999; 245: 127-32.
61. Tsai JF, Margolis HS, Jeng JE, Ho MS, Chang WY, Lin ZY et al. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin Immunol Immunopathol 1995; 75: 39-44.
62. Hiroishi K, Kita H, Kojima M, Okamoto H, Moriyama T, Kaneko T et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 1997; 25: 705-12.
63. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997; 25: 1245-9.
64. Yoshioka K, Higashi Y, Tanaka K, Aiyama T, Takayanagi M, Okumura A et al. Deficiency of antibody response to hypervariable region of hepatitis C virus in patients with chronic hepatitis C. J Hepatol 1996; 24: 649-57.
65. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176: 859-66.
66. Fong TL, Kanel CC, Conrad A, Valinluck B, Charboneau F, Adkins RH. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994; 19: 554-7.
67. Zibert A, Kraas W, Meisel H, Jung G, Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 1997; 71: 4123-7.
68. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistance, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 1999; 73: 1118-26.
69. Cane EJ, Maertens G, Ducatteeuw A, Qian KP, Lau JY, Jones H et al. Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. Transplantation 1999; 67: 78-84.
70. Chang KM, Rehermann B, Chisari FV. Immunopathology of hepatitis C. Springer Semin Immunopathol 1997; 19: 57-68.
71. Antipa C, Ruta S, Cernescu C. Serological profile assessment of the infection with hepatitis C virus (HCV) in haemophiliacs and thalassemic patients. Rom J Virol 1996; 47: 3-11.
72. Kao JH, Chen PJ, Wang JT, Yang PM, Lai MY, Wang TH et al. Superinfection by homotypic virus in hepatitis C virus carriers: Studies on patients with post-transfusion hepatitis. J Med Virol 1996; 50: 303-8.
73. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Vannest G et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-8.
74. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996; 93: 1759-63.
75. Nakano I, Maertens G, Major ME, Vitvitski L, Dubuisson J, Fournillier A et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997; 71: 7101-9.
76. Tedeschi V, Akatsuka T, Shih JW, Battegay M, Feinstone SM. A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology 1997; 25: 459-62.
77. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997; 158: 1231-7.
78. Inchauspe G, Major ME, Nakano I, Vitvitski L, Trepo C. DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 1997; 15: 853-6.
79. Delmastro P, Meola A, Monaci P, Cortese R, Galfre G. Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine 1997; 15: 1276-85.
80. Hiranuma K, Tamaki S, Nishimura Y, Kusuki S, Isogawa M, Kim G et al. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J Gen Virol 1999; 80: 187-93.
81. Lee DJ, Corr M, Carson DA. Control of immune responses by gene immunization. Ann Med 1998; 30: 460-8.